[Skip to Content]
[Skip to Content Landing]
November 5, 2003

High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis

Author Affiliations

Author Affiliations: Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia.

JAMA. 2003;290(17):2322-2324. doi:10.1001/jama.290.17.2322

Plasma levels of high-density lipoprotein cholesterol (HDL-C) and its major protein apolipoprotein A-I (apoA-I) are consistently inversely associated with coronary heart disease (CHD) risk in observational studies.1 Furthermore, studies in animals over the last 2 decades have established that intravenous infusion of HDL or apoA-I or genetic overexpression of apoA-I can substantially reduce the progression and even induce regression of preexisting atherosclerosis.2 Based on these data, HDL and apoA-I have become a major target for the development of new therapies for atherosclerosis.3,4